Newron receives funding from Italian government
This article was originally published in Scrip
Executive Summary
Newron Pharmaceuticals has been awarded €5 million from the Italian research ministry towards its €5.3 million R&D programme. The grant will fund R&D expenses incurred during the two year period which began July 1st, last year, as well as training costs for an 18-month period which began at the start of this year. €260,000 of the funding will be used for training activities. Newron will pay 0.5% interest on 58% of the grant, which is to be repaid within 10 years, while the remainder of the grant is non-reimbursable. Newron acquired the UK biopharmaceutical company Hunter-Fleming for €8 million up front in April (Scrip Online, April 30th, 2008).
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.